These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3166076)

  • 1. RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation.
    Padua RA; Carter G; Hughes D; Gow J; Farr C; Oscier D; McCormick F; Jacobs A
    Leukemia; 1988 Aug; 2(8):503-10. PubMed ID: 3166076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia.
    Lübbert M; Mirro J; Kitchingman G; McCormick F; Mertelsmann R; Herrmann F; Koeffler HP
    Oncogene; 1992 Feb; 7(2):263-8. PubMed ID: 1549347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia.
    Nakagawa T; Saitoh S; Imoto S; Itoh M; Tsutsumi M; Hikiji K; Nakamura H; Matozaki S; Ogawa R; Nakao Y
    Oncology; 1992; 49(2):114-22. PubMed ID: 1574246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of ras gene activation in myeloid leukemic cells.
    Lübbert M; Jonas D; Miller CW; Herrmann F; Mertelsmann R; McCormick F; Koeffler HP
    Oncogene; 1990 Apr; 5(4):583-7. PubMed ID: 2183160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes.
    Neubauer A; Greenberg P; Negrin R; Ginzton N; Liu E
    Leukemia; 1994 Apr; 8(4):638-41. PubMed ID: 7512175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.
    Christiansen DH; Andersen MK; Desta F; Pedersen-Bjergaard J
    Leukemia; 2005 Dec; 19(12):2232-40. PubMed ID: 16281072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of K-ras by codon 13 mutations in C57BL/6 X C3H F1 mouse tumors induced by exposure to 1,3-butadiene.
    Goodrow T; Reynolds S; Maronpot R; Anderson M
    Cancer Res; 1990 Aug; 50(15):4818-23. PubMed ID: 2196119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of N-ras point mutations with specific chromosomal abnormalities in primary myelodysplastic syndrome.
    de Souza Fernandez T; Menezes de Souza J; Macedo Silva ML; Tabak D; Abdelhay E
    Leuk Res; 1998 Feb; 22(2):125-34. PubMed ID: 9593469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
    Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
    Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome.
    Horiike S; Misawa S; Nakai H; Kaneko H; Yokota S; Taniwaki M; Yamane Y; Inazawa J; Abe T; Kashima K
    Leukemia; 1994 Aug; 8(8):1331-6. PubMed ID: 8057669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of protooncogenes in spontaneously occurring non-liver tumors from C57BL/6 x C3H F1 mice.
    Candrian U; You M; Goodrow T; Maronpot RR; Reynolds SH; Anderson MW
    Cancer Res; 1991 Feb; 51(4):1148-53. PubMed ID: 1997158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS mutations in patients following cytotoxic therapy for lymphoma.
    Carter G; Hughes DC; Clark RE; McCormick F; Jacobs A; Whittaker JA; Padua RA
    Oncogene; 1990 Mar; 5(3):411-6. PubMed ID: 2179819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic aberrations in the development and subsequent progression of myelodysplastic syndrome.
    Misawa S; Horiike S; Kaneko H; Kashima K
    Leukemia; 1997 Apr; 11 Suppl 3():533-5. PubMed ID: 9209448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of ras gene mutations in acute myeloid leukemia by the polymerase chain reaction and oligonucleotide probes.
    Chin YM; Bosco JJ; Koh CL
    Singapore Med J; 1992 Feb; 33(1):48-50. PubMed ID: 1598607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 12th codon mutation resulting in c-N-ras activation in acute myelogenous leukemia.
    Needleman SW; Devine SE; Kraus MH
    Leukemia; 1988 Feb; 2(2):91-3. PubMed ID: 3278172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ras gene activation in a minor proportion of the blast population in acute myeloid leukemia.
    Toksoz D; Farr CJ; Marshall CJ
    Oncogene; 1987; 1(4):409-13. PubMed ID: 3330783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes.
    Lyons J; Janssen JW; Bartram C; Layton M; Mufti GJ
    Blood; 1988 Jun; 71(6):1707-12. PubMed ID: 3285909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
    Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC
    Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome.
    Hirai H; Kobayashi Y; Mano H; Hagiwara K; Maru Y; Omine M; Mizoguchi H; Nishida J; Takaku F
    Nature; 1987 Jun 4-10; 327(6121):430-2. PubMed ID: 3295562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.